Observational studyEuropean journal of pediatrics2025
Response to anticholinergic therapy and its predictors in pediatric overactive bladder.
Observational study in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07046156 (Evaluation of Anticholinergic Treatment Response and Predictive Factors in Pediatric Overactive Bladder), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Anticholinergic Treatment Response and Predictive Factors in Pediatric Overactive Bladder
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe treatment of overactive bladder (OAB), which is commonly seen in children, is primarily based on standard urotherapy and anticholinergics. This study aimed to evaluate the efficacy of anticholinergics in OAB and clinical factors affecting treatment outcomes.
methodsThe data of children with OAB included demographic and clinical data, Dysfunctional Voiding Symptom Score, and voiding diaries. Three anticholinergic agents-oxybutynin, propiverine, and tolterodine-were assessed. The treatment response was categorized as complete, partial, or non-response.
resultsOf 164 patients, 20.1% responded to urotherapy, while the remaining (mean age 7.7 ± 3.3 years; 54.2% male) required anticholinergic treatment. The first-line anticholinergic was oxybutynin in 86 (65.6%) patients, propiverine in 30 (22.9%), and tolterodine in 15 (11.5%). Treatment outcomes were similar (p = 0.35), but propiverine and tolterodine had fewer side effects than oxybutynin (p = 0.027). The overall success rate was 95.4% (n = 125), with 85.5% (n = 112) achieving complete and 9.9% (n = 13) partial responses. Higher daily voids were correlated with raised odds of a partial/no response to initial anticholinergic (OR: 1.15, 95% CI: 1.01-1.32, p = 0.039). Tolterodine correlated with decreased odds of partial/no response (OR: 0.15, 95% CI: 0.03-0.77, p = 0.023).
conclusionAnticholinergics show similar efficacy in treating OAB, though oxybutynin is associated with more side effects. Tolterodine reduced the odds of non-complete response, while a higher daily voids increased it.
trial registrationNCT07046156, date of registration: 30/06.2025 retrospectively registered. WHAT IS KNOWN: • Treatment of overactive bladder in children mainly relies on standard urotherapy and anticholinergic agents. WHAT IS NEW: • Oxybutynin caused more adverse effects than tolterodine or propiverine despite similar treatment outcomes. • Tolterodine increased the likelihood of complete response, while a higher number of daily voids reduced it.
Indexed as
Identifiers
41182445What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.